Mark A Meltz
CIK 1771329 · General Counsel · last filed 2026-02-11
Mark A Meltz is a General Counsel who has filed 16 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for LYEL, was dated Feb 11, 2026.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
16
$0
Holdings By Company
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-11 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2025-06-11 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2024-04-05 | — | Disp (D) | −27,578 | $0 | |
| 2024-03-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −558 | -$1.4K | EDGAR |
| 2023-12-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −541 | -$1.2K | EDGAR |
| 2023-09-06 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −541 | -$1.3K | EDGAR |
| 2023-06-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −541 | -$2.3K | EDGAR |
| 2023-03-03 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −638 | -$3.3K | EDGAR |
| 2023-02-14 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-02 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −541 | -$4.2K | EDGAR |